Associate Professor Daniel Thomas

Associate Professor Haematology

Adelaide Medical School

Faculty of Health and Medical Sciences

With unique training experience at the Stanford University School of Medicine, Daniel Thomas is a clinical haematologist and cancer scientist whose goals are to develop new drugs and better outcomes for the treatment of rare and hard-to-treat cancers and lead a creative and innovative cancer research laboratory. The core values in Dan's lab are Creativity (not being afraid to try something new), Compassion (identifying with cancer patients and their carers to learn what really matters) and Generosity (sharing new technologies to other researchers to move the field forward).

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Dan is currently Program Director for Blood Cancers at SAHMRI and leads the Myeloid Metabolism Lab located on Level 5 of the main SAHMRI building (Precision Medicine, Cancer Theme, adjacent to the Royal Adelaide Hospital and 10 minutes from Adelaide International Airport). The lab is focused on interplay between cancer, metabolism and epigenetics. Dr Daniel Thomas is a clinical haematologist and pathologist whose goals in research are to develop new drugs for the treatment of cancer using expanded human myeloid progenitors, mass spectrometry and computational tools and has 6 filed patents for encompassing novel treatments for blood cancer. He has had post-doctoral training experience at the Stanford School of Medicine, Institute of Stem Cell & Regenerative Medicine, led by Irving Weissman and direct mentoring from Professor Ravindra Majeti (CD47 and pre-leukaemic stem cells). Key equipment accessible from Dan's laboratory including Seahorse Xfe96, Vistaflux software with Agilent 6546 Q-ToF metabolomics solution, BRAVO liquid handing robot, human metabolome shRNA bar-coded library, 10X single cell transcriptomics, ARIA FACS sorter & serial blood cancer patient samples. If you are passionate about thinking outside the square to improve the treatment of cancer, please contact Dr Thomas about potential student internships.

The Thomas Lab has a strong track record in finding new druggable targets in cancer and predicting mutations that respond to specific targeted therapies as well as repurposing drugs for new uses in cancer. Some of the discoveries already in the clinic or are under clinical investigation, including a humanized monoclonal antibody for the treatment of myelofibrosis (EMBO Reports, 2022), JAK2 mutations (Blood Cancer Discovery, 2023) and precision dietetics for IDH1 mutated cancers (Cancer Discovery, 2022) ( https://aacrjournals.org/bloodcancerdiscov/article-abstract/5/2/114/734869/IDH1-Mutant-Preleukemic-Hematopoietic-Stem-Cells?redirectedFrom=fulltext ) . Dan leads an international biannual conference, New Directions in Leukaemia Research (NDLR 2022 Brisbane, NDLR 2024 Adelaide and NDLR 2026 Adelaide) that brings scientists and doctors together to discover new treatments for blood cancers and leukaemia and the 5th National Cancer & Metabolism conference ( https://sahmri.org.au/australian-cancer-metabolism-meeting-2024).

Dan's lab is leading the first precision medicine trial nationwide for a rare and poor prognosis blood cancer called CMML (chronic myelomonocytic leukaemia) using an anti-GM-CSF neutralizing antibody https://ashpublications.org/ashclinicalnews/news/8658/Patients-With-CMML-Show-Durable-Response-to . Recently, members of his team led by Professor Hiwase described a new form of autoimmune disease linked to IDH1 mutations in cancer (Blood, 2024).

Other research contributions include (i) mutation-specific drug targets for acute myeloid leukaemia (EZH2 for AML with WT1 mutation, Blood 2015; Bcl2 as a target for cancer with IDH1 mutation, Nature Med 2016; ROS activation for AML with NPM1 mutation, Leukemia 2014; ACC1 for AML with IDH1 mutation, Nature Com, 2017), (ii) prediction of 145,891 synthetic partners for 3,120 recurrent mutations for 12 cancer types (Leukemia 2019, first author and co-inventor Nature Com, 2017, (iii) pre-clinical development of a biological therapy (humanized monoclonal antibody directed against CD123 Cell Stem Cell, 2009, Leukemia 2014) (iv) pre-clinical development of a biological therapy for myelofibrosis (Science Adv 2018), (v) repurposing medicines for treatment of leukaemia (JCI 2020, Scientific Reports 2019, J of Hepatology 2020) and (iv) translational experience in the Stanford Alliance for Innovative Medicines program.

Dr Thomas has been awarded a number of prizes for his work including the CSL Centenary Fellowship ($1.25M), K99-R00 Pathway to Independence award by the National Cancer Institute, NHMRC PhD award, Albert Bakie Medal, Douglas Hardy Prize, Nimmo Prize and CJ Martin Biomedical Fellowship, The Hospital Research Foundation 2020, 2 Ideas grants NHMRC 2020, MRFF funding 2020 for a precision medicine trial "Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort ". Dr Thomas received competitive grant funding for the 2020, 2022 and 2023 Translational Research Program/ Synergistic Team Awards from United States Leukemia & Lymphoma Society co-funded by The Leukaemia Foundation and Snowdome.

The over-arching goal of Dan’s research is to find novel mutation-specific drug targets for somatic mutations, especially in poor prognosis and difficult to treat cancer types, using leukemia as a test bed. The lab has unique skills in developing humanized in vivo models for AML, isolation and testing of pre-leukemia stem cells and bioinformatic algorithms together with key academic and industry networks.

Links to more information about The Myeloid Metabolism Lab:-

https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-21-0218/710553/Dysregulated-lipid-synthesis-by-oncogenic-IDH1

https://www.abc.net.au/news/2022-03-25/researchers-discover-potential-treatment-for-rare-cancer/100938498

https://www.leukaemia.org.au/stories/an-antibody-for-myelofibrosis-thats-a-true-discovery/

https://www.leukaemia.org.au/stories/a-new-era-of-medicine/

https://www.snowdome.org.au/science/prof-ravi-majeti-and-dr-daniel-thomas-are-uncovering-new-methods-to-switch-off-and-destroy-cancer-cells/

https://www.adelaide.edu.au/newsroom/news/list/2020/06/29/162-million-for-rare-cancer-research

https://www.cslfellowships.com.au/fellows-archive/associate-professor-daniel-thomas-bio

https://ndlr.com.au/

Appointments

Date	Position	Institution name
2022 - ongoing	Haematology Consultant	Royal Adelaide Hospital
2019 - ongoing	Titleholder	Stanford University School of Medicine
2019 - ongoing	Myeloid Metabolism Lab Leader and Program Leader Blood Cancer, Precision Medicine Theme	South Australian Health and Medical Research Institute
2019 - ongoing	CSL Fellow and Associate Professor	The University of Adelaide
2017 - 2019	Instructor/Junior Faculty	Stanford University School of Medicine
2010 - 2012	Staff Specialist	Royal Adelaide Hospital
2000 - 2000	Resident	Royal Adelaide Hospital

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2018	Award	Stanford Alliance of Innovative Medicines Award	Stanford University	United States	-
2015	Award	Honorary Award for Outstanding Presentation, Stanford Hematology-Oncology Retreat	Stanford University School of Medicine	United States	-
2015	Award	Outstanding External Grant Reviewer for 2014	National Health and Medical Research Council of Australia	Australia	-
2014	Award	Best Publication for Previous Year	Centre for Cancer Biology	Australia	-
2014	Award	Leukemia Foundation New Investigator Award	Leukemia Foundation	Australia	-
2014	Award	Outstanding Young Investigator Award, New Directions in Leukemia Research Conference	New Directions in Leukemia Research	Australia	-
2012	Distinction	Dean’s Commendation for Doctoral Thesis Excellence for PhD	The University of Adelaide	Australia	-
2012	Fellowship	CJ Martin Overseas Biomedical Fellowship	NHMRC	Australia	$375,828
2011	Fellowship	HOTT Haematology/Oncology Targetted Therapy Fellowship	Haematology Society of Australia & New Zealand/COSA/Roche/COGA	Australia	-
2010	Award	Nimmo Prize, Best Full-Time Research	Royal Adelaide Hospital	Australia	-
2010	Award	Outstanding Research Presentation Prize, New Directions in Leukaemia Conference	New Directions in Leukaemia Research (NDLR)	Australia	-
2010	Fellowship	HSANZ Haematology Targeted Therapy Fellowship	The Haematology Society of Australia and New Zealand	Australia	-
2008	Award	National Adult Medicine Research Award	Royal Australasian College of Physicians	Australia	-
2007	Award	Albert Baikie Memorial Medal	Haematology Society of Australia & New Zealand	Australia	-
2007	Award	John Chalmers Prize for Best Medical Research Presentation	Royal Australasian College of Physicians	Australia	-
2007	Scholarship	The NHMRC Postgraduate Scholarship	National Health & Medical Research Council	Australia	-
2004	Award	Hugh Gilmore Prize for Best Presentation of Medical Research by a Physician in Training	Royal Adelaide Hospital	Australia	-

Education

Date	Institution name	Country	Title
2012	University of Adelaide	Australia	PhD
2000	University of Adelaide	Australia	Bachelor of Medicine and Bachelor of Surgery
1998	University of Adelaide	Australia	Bachelor of Medical Science (Honours)

Postgraduate Training

Date Title Institution Country

2012 - 2013 Postdoctoral Fellow Stanford University School of Medicine United States
Certifications

Date Title Institution name Country

2007 Fellow (FRACP) Royal Australasian College of Physicians Australia

2007 Fellow (FRCPA) Royal College of Pathologists of Australasia Australia
Research Interests

Cancer Biology and Clinical Oncology

Date	Title	Institution	Country
2012 - 2013	Postdoctoral Fellow	Stanford University School of Medicine	United States

Date	Title	Institution name	Country
2007	Fellow (FRACP)	Royal Australasian College of Physicians	Australia
2007	Fellow (FRCPA)	Royal College of Pathologists of Australasia	Australia

Journals

Year	Citation
2025	Kan, W. L., Weekley, C. M., Nero, T. L., Hercus, T. R., Yip, K. H., Tumes, D. J., . . . Parker, M. W. (2025). The β Common Cytokine Receptor Family Reveals New Functional Paradigms From Structural Complexities. Immunological Reviews, 329(1), e13430-1-e13430-25. DOI Scopus1 WoS3
2025	Robinson, N., Polara, R., & Thomas, D. (2025). IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer. Signal Transduction and Targeted Therapy, 10(1), 52-1-52-3. DOI Scopus2 WoS1
2025	Hansman, D. S., Lim, K., Thomas, D., Casson, R. J., & Peet, D. J. (2025). Distinct metabolome and flux responses in the retinal pigment epithelium to cytokines associated with age-related macular degeneration: comparison of ARPE-19 cells and eyecups. Scientific Reports, 15(1), 13012-1-13012-17. DOI
2025	Shah, M. V., Hung, K., Baranwal, A., Wechalekar, G., Al-Kali, A., Toop, C. R., . . . Hiwase, D. (2025). Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.. Blood Cancer Journal, 15(1), 88-1-88-11. DOI Scopus2 WoS1
2025	Kok, C. H., Al-Kali, A., Thomas, D., He, R., Kutyna, M. M., Alkhateeb, H., . . . Hiwase, D. K. (2025). RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm. Blood Advances, 9(15), 3814-3818. DOI
2024	Landberg, N., Köhnke, T., Feng, Y., Nakauchi, Y., Fan, A. C., Linde, M. H., . . . Majeti, R. (2024). IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.. Blood Cancer Discov, 5(2), 114-131. DOI Scopus16 WoS15 Europe PMC8
2024	Calabrese, C., Nolte, H., Pitman, M. R., Ganesan, R., Lampe, P., Laboy, R., . . . Robinson, N. (2024). Mitochondrial translocation of TFEB regulates complex I and inflammation.. EMBO Reports, 25(2), 704-724. DOI Scopus8 WoS7 Europe PMC7
2024	Hong, L. E., Wechalekar, M. D., Kutyna, M. M., Small, A., Lim, K., Thompson-Peach, C. A., . . . Hiwase, D. K. (2024). IDH-Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation. Blood, 143(18), 1873-1877. DOI Scopus7 WoS8 Europe PMC6
2024	Hansman, D. S., Ma, Y., Thomas, D., Smith, J. R., Casson, R. J., & Peet, D. (2024). Metabolic Reprogramming of the Retinal Pigment Epithelium by Cytokines Associated with Age-related Macular Degeneration. Bioscience Reports, 44(4), BSR20231904.-1-BSR20231904.-20. DOI Scopus6 WoS7 Europe PMC5
2024	Wechalekar, M. D., Zhao, L. -P., Kutyna, M. M., Hong, L. E., Li, J., Hung, K., . . . Hiwase, D. K. (2024). Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features. Blood Cancer Journal, 14(1), 116-1-116-5. DOI Scopus1 WoS1 Europe PMC1
2024	Lim, K., Kan, W. L., Nair, P. C., Kutyna, M., Lopez, A. F., Hercus, T., . . . Thomas, D. (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19(9), e0310641-1-e0310641-19. DOI Scopus1
2023	Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A., Lim, K., . . . Majeti, R. (2023). Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery, 13(2), 496-515. DOI Scopus39 WoS39 Europe PMC32
2023	Hiwase, D. K., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., . . . Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091. DOI Scopus24 WoS21 Europe PMC20
2023	Foßelteder, J., Pabst, G., Sconocchia, T., Schlacher, A., Auinger, L., Kashofer, K., . . . Reinisch, A. (2023). Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. Leukemia, 37(4), 843-853. DOI Scopus9 Europe PMC10
2023	Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., . . . Hiwase, D. K. (2023). TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 13(1), 51-1-51-9. DOI Scopus26 WoS26 Europe PMC25
2023	Thompson-Peach, C. A. L., Foßelteder, J., Reinisch, A., & Thomas, D. (2023). Thrombopoietin-independent Megakaryocyte Differentiation of Hematopoietic Progenitor Cells from Patients with Myeloproliferative Neoplasms. Bio-protocol, 13(2). DOI
2023	Kan, W. L., Dhagat, U., Hercus, T. R., Kaufmann, K. B., Nero, T. L., Zeng, A. G. X., . . . Lopez, A. (2023). Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia. Cancer Discovery, 13(8), 1922-1947. DOI Scopus8 WoS8 Europe PMC7
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discovery, 4(5), 352-364. DOI Scopus12 WoS11 Europe PMC10
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. DOI
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 2 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. DOI
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Methods from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. DOI
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Figure S1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. DOI
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Movie from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. DOI
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 2 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. DOI
2023	Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. DOI
2023	Sharplin, K., Proudman, W., Chhetri, R., Tran, E. N. H., Choong, J., Kutyna, M., . . . Hiwase, D. (2023). A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data. Cancers, 15(16), 1-14. DOI Scopus3 WoS3 Europe PMC3
2022	Tvorogov, D., Thompson-Peach, C. A. L., Foßelteder, J., Dottore, M., Stomski, F., Onnesha, S. A., . . . Lopez, A. F. (2022). Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody. EMBO Reports, 23(4), e52904-1-e52904-12. DOI Scopus20 WoS20 Europe PMC19
2022	Lewis, A. C., Pope, V. S., Tea, M. N., Li, M., Nwosu, G. O., Nguyen, T. M., . . . Pitson, S. M. (2022). Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.. Blood, 139(26), 3737-3751. DOI Scopus33 WoS29 Europe PMC32
2022	Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 1-12. DOI Scopus17 WoS17 Europe PMC13
2022	Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.. Nat Commun, 13(1), 4131. DOI Scopus2 WoS2 Europe PMC1
2022	Downes, C. E., McClure, B. J., McDougal, D. P., Heatley, S. L., Bruning, J. B., Thomas, D., . . . White, D. L. (2022). JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. Frontiers in Cell and Developmental Biology, 10, 1-34. DOI Scopus24 WoS21 Europe PMC17
2022	Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689. DOI Scopus17 WoS17 Europe PMC17
2022	Nakauchi, Y., Azizi, A., Thomas, D., Corces, M. R., Reinisch, A., Sharma, R., . . . Majeti, R. (2022). The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia. Blood Cancer Discovery, 3(4), 346-367. DOI Scopus33 WoS30 Europe PMC28
2021	Sharplin, K., Wee, L. Y. A., Singhal, D., Edwards, S., Danner, S., Lewis, I., . . . Hiwase, D. K. (2021). Outcomes and health care utilization of older patients with acute myeloid leukemia.. Journal of geriatric oncology, 12(2), 243-249. DOI Scopus5 WoS5 Europe PMC8
2021	Ross, D. M., Babon, J. J., Tvorogov, D., & Thomas, D. (2021). Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. Haematologica, 106(5), 1244-1253. DOI Scopus22 WoS20 Europe PMC15
2021	Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256. DOI Scopus46 WoS43 Europe PMC37
2021	Lim, K., Thompson-Peach, C., & Thomas, D. (2021). Neonatal heel prick mass spectrometry identifies metabolic predictors of AML latency. Leukemia Research, 109, 1-3. DOI Scopus2 WoS1
2021	Thomas, D. (2021). Machine learning finds new AML subtypes. Blood, 138(19), 1790-1792. DOI Scopus2
2021	Benard, B. A., Leak, L. B., Azizi, A., Thomas, D., Gentles, A. J., & Majeti, R. (2021). Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications, 12(1), 1-13. DOI Scopus45 Europe PMC49
2020	Guan, Y., Chen, X., Wu, M., Zhu, W., Arslan, A., Takeda, S., . . . Peltz, G. (2020). The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy. Journal of Hepatology, 72(4), 16 pages. DOI Scopus51 Europe PMC37
2020	Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M., Gars, E., . . . Majeti, R. (2020). Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. Journal of Clinical Investigation, 130(4), 1843-1849. DOI Scopus25 Europe PMC19
2019	Benard, B., Gentles, A. J., Köhnke, T., Majeti, R., & Thomas, D. (2019). Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia, 33(4), 826-843. DOI Scopus18 Europe PMC15
2019	Benard, B., & Thomas, D. (2019). Predicting response to new drugs in AML from simulation modelling: Value of the BEAT AML project as a validation resource. Leukemia Research, 80, 43-44. DOI Scopus1 Europe PMC1
2019	Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019). Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports, 9(1), 16775. DOI Scopus18 Europe PMC13
2018	Gars, E., Kaur, S., & Thomas, D. (2018). Endothelin receptor emerges as a potential target of Hoxa9-mediated leukemogenesis. Leukemia Research, 75, 69-70. DOI
2018	Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . . . Lopez, A. F. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances, 4(11), 1-12. DOI Scopus45 WoS45 Europe PMC45
2017	Powell, J., Lewis, A., Zhu, W., Toubia, J., Pitman, M., Wallington-Beddoe, C., . . . Pitson, S. (2017). Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.. Blood, 129(6), 771-782. DOI Scopus83 WoS78 Europe PMC67
2017	Sinha, S., Thomas, D., Chan, S., Gao, Y., Brunen, D., Torabi, D., . . . Dill, D. L. (2017). Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications, 8(1), 1-13. DOI Scopus80 Europe PMC52
2017	Thomas, D., & Majeti, R. (2017). Optimizing next-generation AML therapy: Activity of mutant IDH2 inhibitor AG-221 in preclinical models. Cancer Discovery, 7(5), 459-461. DOI Scopus15 Europe PMC10
2017	Thomas, D., & Majeti, R. (2017). Biology and relevance of human acute myeloid leukemia stem cells. Blood, 129(12), 1577-1585. DOI Scopus384 Europe PMC319
2016	Thomas, D., & Majeti, R. (2016). Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell, 19(1), 1-2. DOI Scopus7 Europe PMC9
2016	Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Truong Nguyen, L. X., Chan, S. M., . . . Mitchell, B. S. (2016). Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget, 7(46), 74917-74930. DOI Scopus9 Europe PMC9
2016	Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D., Hong, W. J., . . . Majeti, R. (2016). A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine, 22(7), 812-821. DOI Scopus182 Europe PMC151
2016	Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., . . . Verrills, N. M. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7(30), 47465-47478. DOI Scopus42 WoS41 Europe PMC30
2015	Mazumdar, C., Shen, Y., Xavy, S., Zhao, F., Reinisch, A., Li, R., . . . Majeti, R. (2015). Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell, 17(6), 675-688. DOI Scopus171 Europe PMC158
2015	Raval, A., Behbehani, G. K., Nguyen, L. X. T., Thomas, D., Kusler, B., Garbuzov, A., . . . Mitchell, B. S. (2015). Reversibility of defective hematopoiesis caused by telomere shortening in telomerase knockout mice. PLoS ONE, 10(7), 1-20. DOI Scopus23 Europe PMC22
2015	Reinisch, A., Etchart, N., Thomas, D., Hofmann, N. A., Fruehwirth, M., Sinha, S., . . . Strunk, D. (2015). Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood, 125(2), 249-260. DOI Scopus200 Europe PMC173
2015	Sinha, S., Thomas, D., Yu, L., Gentles, A. J., Jung, N., Corces-Zimmerman, M. R., . . . Majeti, R. (2015). Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood, 125(2), 316-326. DOI Scopus42 Europe PMC32
2015	Reinisch, A., Chan, S. M., Thomas, D., & Majeti, R. (2015). Biology and clinical relevance of acute myeloid leukemia stem cells. Seminars in Hematology, 52(3), 150-164. DOI Scopus55 Europe PMC45
2015	Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W. J., . . . Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21(2), 178-184. DOI Scopus496 Europe PMC413
2014	Busfield, S., Biondo, M., Wong, M., Ramshaw, H., Lee, E., Ghosh, S., . . . Nash, A. (2014). Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia, 28(11), 2213-2221. DOI Scopus124 WoS113 Europe PMC90
2013	Lonic, A., Powell, J., Kong, Y., Thomas, D., Holien, J., Truong, N., . . . Guthridge, M. (2013). Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein Kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation. Journal of Biological Chemistry, 288(21), 14874-14885. DOI Scopus15 WoS14 Europe PMC13
2013	Thomas, D., Powell, J., Vergez, F., Segal, D., Nguyen, N., Baker, A., . . . Guthridge, M. (2013). Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 122(5), 738-748. DOI Scopus56 WoS55 Europe PMC48
2013	Lim, Y., Wright, J., Attema, J., Gregory, P., Bert, A., Smith, E., . . . Goodall, G. (2013). Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. Journal of Cell Science, 126(10), 2256-2266. DOI Scopus172 WoS156 Europe PMC140
2013	Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14. DOI Scopus20 WoS17 Europe PMC20
2013	Huang, M., Thomas, D., Li, M. X., Feng, W., Chan, S. M., Majeti, R., & Mitchell, B. S. (2013). Role of cysteine 288 in nucleophosmin cytoplasmic mutations: Sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia, 27(10), 1970-1980. DOI Scopus30 Europe PMC30
2012	Hercus, T., Broughton, S., Ekert, P., Ramshaw, H., Perugini, M., Grimbaldeston, M., . . . Lopez, A. (2012). The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors, 30(2), 63-75. DOI Scopus62 WoS58 Europe PMC50
2010	Lopez, A., Hercus, T., Ekert, P., Littler, D., Guthridge, M., Thomas, D., . . . Parker, M. (2010). Molecular basis of cytokine receptor activation. IUBMB Life, 62(7), 509-518. DOI Scopus63 WoS57 Europe PMC43
2010	Roberts, K. G., Smith, A. M., McDougall, F., Carpenter, H., Horan, M., Neviani, P., . . . Verrills, N. M. (2010). Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Research, 70(13), 5438-5447. DOI Scopus124 WoS121 Europe PMC92
2009	Jin, L., Lee, E., Ramshaw, H., Busfield, S., Peoppl, A., Wilkinson, L., . . . Lock, R. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5(1), 31-42. DOI Scopus462 WoS416 Europe PMC371
2009	Powell, J., Thomas, D., Barry, E., Kok, C., McClure, B., Tsykin, A., . . . Guthridge, M. (2009). Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 114(23), 4859-4870. DOI Scopus53 WoS51 Europe PMC46
2009	Hercus, T., Thomas, D., Guthridge, M., Ekert, P., King-Scott, J., Parker, M., & Lopez, A. (2009). The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood, 114(7), 1289-1298. DOI Scopus260 WoS249 Europe PMC195
2008	Lee, S., Ho, S., Thomas, D., Giri, P., Lee, H., Sia, H., . . . Sullivan, T. (2008). A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution. International Journal of Laboratory Hematology (Print Edition), 30(6), 473-479. DOI Scopus3 WoS2 Europe PMC3
2006	Mitchell, E., Thomas, D., & Burnet, R. (2006). Testosterone improves motor function in Parkinson's disease. Journal of Clinical Neuroscience, 13(1), 133-136. DOI Scopus52 Europe PMC32
2006	Guthridge, M., Powell, J., Barry, E., Stomski, F., Mc Clure, B., Ramshaw, H., . . . Lopez, A. (2006). Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO Journal, 25(3), 479-489. DOI Scopus72 WoS71 Europe PMC63
2004	Thomas, D., Vadas, M., & Lopez, A. (2004). Regulation of haematopoiesis by growth factors - emerging insights and therapies. Expert Opinion on Biological Therapy, 4(6), 869-879. DOI Scopus17 WoS16 Europe PMC15
1999	Stomski, F., Dottore, M., Winnall, W., Guthridge, M., Woodcock, J., Bagley, C., . . . Lopez, A. (1999). Identification of a 14-3-3 binding sequence in the common B chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors that is serine-phosphorylated by GM-CSF. Blood, 94(6), 1933-1942. DOI Scopus46 WoS39 Europe PMC26
1998	Guthridge, M. A., Stomski, F. C., Thomas, D., Woodcock, J. M., Bagley, C. J., Berndt, M. C., & Lopez, A. F. (1998). Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells, 16(5), 301-313. DOI Scopus158 WoS150 Europe PMC118

Books

Year	Citation
2005	Thomas, D., Guthridge, M., Woodcock, J., & Lopez, A. (2005). Protein Signaling in Development and Growth Factor Responses (Vol. 67). G. P. Schatten (Ed.), ELSEVIER ACADEMIC PRESS INC. DOI Scopus37 WoS35 Europe PMC29

Book Chapters

Year Citation

2013 Zola, H., Thomas, D., & Lopez, A. (2013). Monoclonal antibodies: therapeutic uses. In P. Delves (Ed.), eLS (pp. 1-12). Online: Wiley.
DOI

Year	Citation
2013	Zola, H., Thomas, D., & Lopez, A. (2013). Monoclonal antibodies: therapeutic uses. In P. Delves (Ed.), eLS (pp. 1-12). Online: Wiley. DOI

Patents

Year	Citation
2017	Sinha, S., Ravindra, M., Dill, D. L., & Thomas, D. (2017). WO/2017/083716, Determination of Synthetic Lethal Partners of Cancer-Specific Alterations and Methods of Use Thereof. United States.

Date	Project/No.	Investigators	Funding Body	Amount
2023-2025	Bioengineering a Superior Humanized Haematopoietic Niche Derived from Mesenchymal Stem Cells for Pre-Clinical Avatar Cancer Trials. MRF2024427	THOMAS D, Reinisch A, Thompson-Peach C, Powell J, Branford S, Arthur A, Pitson S, Hughes T, Ross D, Edney L.	MRFF Stem Cell Therapies	$854,594
2023	Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis.	THOMAS D	Therapeutic Innovation Australia Pipeline Accelerator	$100,000
2022-2025	Identifying synthetic lethal and microenvironmental targets to improve outcome of therapy-related myeloid neoplasms. 2013617.	Hiwase D, Hahn C, THOMAS D, Gronthos S, Godley L.	Cancer Australia Priority-driven Collaborative Cancer Research Scheme.	$563,770
2022-2025	Identification and Molecular Analysis of Pre-Myelofibrotic Stem Cells. FND000208.	THOMAS D, Majeti R, Lopez A.	Leukemia & Lymphoma Society	US $600,000
2021-2026	Shining Light into the “unknown” on Indigenous and non-Indigenous Australians with Cancer of unknown Primary. MRF2007652	Karapetis C, Brown A, Kichendasse G, Pratt G, Scott H, Vajdic C, Waddell N, Corsini N, THOMAS D, Brown A.	MRFF Improving Diagnosis in Cancers with Low Survival Rates.	$2,401,509
2021-2024	ABOLISH Neuroblastoma: Defining the Aetiology and underlying BiOLogy of neuroblastoma to Innovate and SHape new options for prevention, diagnosis and treatment. MRF2007404.	Khew-Goodall Y, Goodall G, Kirby M, Schwarz Q, Polo J, Wolvetang E, Pillman K, Jessop S, THOMAS D.	MRFF Childhood Cancer Research	$1,420,132
2021-2024	Engineered human stem cells for mutation-specific eradication of myelofibrosis. MRF2008972	THOMAS D, Reinisch A, Ross D, Babon J, Tvorogov D, Nair P, Morris R	MRFF Stem Cell Therapies	$853,275.
2020-2024	Targeting Macromolecule Biosynthesis in Cancer by in vivo Flux Measurement of Primary Cells for Rational Drug Development. IF1320.	THOMAS D	Beat Cancer Project Infrastructure Grant	$153,120
2020-2023	Personalized Metabolic Targeting of Epigenetic AML Mutations Through the Alpha-Ketoglutarate Pathway. ID 6619-21.	Majeti R, THOMAS D.	The Leukemia and Lymphoma Society Translational Research Program	US$649,998.
2020-2023	Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort. APP1201012.	Hughes T, Hiwase D, Ross D, THOMAS D, Yeung D, Lane S, Yong A, Lopez A, Hercus T, Reynolds J.	MRFF Rare Cancers Rare Diseases Unmet Need	$1,619,122
2020-2022	Mutation-Centric Therapy for JAK2 vs CALR Mutated Myelofibrosis. APP1182564.	Lopez A, Tvorogov D, THOMAS D	NHMRC Ideas	$661,237
2020-2022	Employing humanised xenotransplantation models of acute myeloid leukaemia to predict patient outcome and direct therapy. APP1184485.	Pitson S, Powell J, THOMAS D.	NHMRC Ideas	$795,650
2020-2021	Pre-clinical Efficacy of ACC1 as a novel target for IDH1 Mutated Cancer. C-PJ-173-Exper-2019.	THOMAS D.	The Hospital Research Foundation Project Gran	$69,000
2018-2019	Potent and Selective ACC1 inhibitor for Cancer with IDH1 Mutations	THOMAS D, Majeti R.	Stanford University	US $75,000
2017-2022	Discovery of Synthetic Lethal Targets for Recurrent Epigenetic Mutations in Acute Myeloid Leukemia. APP ID 88686.	THOMAS D.	National Cancer Institute	US $1,040,000
2014-2015	Data-Mining for Synthetic Lethal Targets in Acute Myeloid Leukemia.	Majeti R, Dill D. L.	National Institutes of Health	US $500,000
2014-2015	SA PATH Equipment Grant. GNT9000253.	Lopez A, Hughes T, Revesz T, THOMAS D.	NHMRC	$9,634
2012-2017	Targetting Quiescence Signalling Pathways in AML Stem Cells. APP1037514.	THOMAS, D.	NHMRC – Early Career Fellowship	$274,434

Dr Thomas enjoys teaching and supervising 3rd year science students, Masters and PhD students in formal and informal sessions including regular Cancer Metabolism and Epigenetics journal club meetings at Level 4 SAHMRI Boardroom 2.30pm on Mondays

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2023	Principal Supervisor	Discovery of novel metabolic targets against lDH1-mutant intrahepatic cholangiocarcinoma	Doctor of Philosophy	Doctorate	Full Time	Mrs Tasnova Tasnim Nova
2023	Principal Supervisor	Novel Target Discovery for TP53 Mutated clonal Haematopoiesis	Doctor of Philosophy	Doctorate	Full Time	Mr Hossein Anani
2023	Co-Supervisor	Fecal microbiota transplantation as an adjunctive supportive care therapy for haematopoietic stem cell transplantation recipients.	Doctor of Philosophy	Doctorate	Full Time	Miss Anna Li
2023	Principal Supervisor	How Cancer Associated Fibroblasts Modify Stromal Landscape to Advance Malignant Progression of Breast Cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Michael Antoniou
2023	Principal Supervisor	The biological function of tryptophan metabolism in triple-negative breast cancer and cancer stem cells population	Doctor of Philosophy	Doctorate	Full Time	Mr Jamshid Motalebzadeh
2023	Principal Supervisor	Peroxisome Biology in IDH1 Mutated Cancer Cells and Its potential for Target Therapy	Doctor of Philosophy	Doctorate	Full Time	Ms Mahta Moraghebi
2023	Co-Supervisor	Synthetic lethality-based identification of metabolic targets for prostate cancer treatment	Doctor of Philosophy	Doctorate	Full Time	Mr Mohammad Asaad Ibrahim Ismail
2023	Principal Supervisor	Modelling mutations in juvenile myelomonocytic leukaemia and chronic myelomonocytic leukaemia	Doctor of Philosophy	Doctorate	Part Time	Ms Kelly Lim
2022	Principal Supervisor	A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery	Doctor of Philosophy	Doctorate	Full Time	Miss Maha Kamel

Other Supervision Activities

Date	Role	Research Topic	Location	Program	Supervision Type	Student Load	Student Name
2021 - 2022	Principal Supervisor	Discovering Novel Approaches in the Treatment of CALR mutant Myelofibosis	University of Adelaide	-	Master	-	Suraiya Onnesha
2021 - 2021	Principal Supervisor	A human cell model of juvenile myelomonocytic leukemia with a PTPN11 mutation	University of Adelaide	-	Honours	-	Kzandrea Magday
2018 - 2018	Principal Supervisor	Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethality vulnerability	Stanford University	-	Other	-	Satinder Kaur

Mentoring

Date Topic Location Name

2019 - 2023 Clonal architecture predicts clinical outcome and drug sensitivity Stanford University Brooks Bernard

Date	Topic	Location	Name
2019 - 2023	Clonal architecture predicts clinical outcome and drug sensitivity	Stanford University	Brooks Bernard

Committee Memberships

Date	Role	Committee	Institution	Country
2022 - ongoing	Member	Acute Leukaemia and Myelodysplasia Working Committee	Australasian Leukaemia and Lymphoma Group	Australia
2022 - ongoing	Member	Braggs Comprehensive Cancer Centre	Adelaide Health Innovation Partnership	Australia

Review, Assessment, Editorial and Advice

Date Title Type Institution Country

2019 - ongoing Associate Reviewer Peer Review Blood United States

2019 - ongoing Editor Peer Review PLOS ONE United States

Date	Title	Type	Institution	Country
2019 - ongoing	Associate Reviewer	Peer Review	Blood	United States
2019 - ongoing	Editor	Peer Review	PLOS ONE	United States

Position: Associate Professor Haematology
Phone: 81284317
Email: daniel.thomas@adelaide.edu.au
Campus: North Terrace
Building: Adelaide Health and Medical Sciences, floor 6
Org Unit: Medical Specialties

Associate Professor Daniel Thomas

Appointments

Awards and Achievements

Education

Postgraduate Training

Certifications

Research Interests

Journals

Books

Book Chapters

Patents

Current Higher Degree by Research Supervision (University of Adelaide)

Other Supervision Activities

Mentoring

Committee Memberships

Review, Assessment, Editorial and Advice

Connect With Me

External Profiles